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Recombinant vesicular stomatitis viruses have been developed as high-level expression vectors which serve as effective
vaccine vectors in animals (Roberts et al., 1998, J. Virol. 72, 4704–4711; Roberts et al., 1999, J. Virol. 73, 3723–3732). Here we
show that two genes can be expressed simultaneously from a single, live-attenuated VSV recombinant. The genes used
encode the Pr55gag protein precursor of HIV-1 (1.7-kb gene) and an HIV-1 envelope (Env) protein (2.4 kb gene). Our results
show that VSV can accommodate up to a 40% increase in genome size with only a threefold reduction in virus titer.
Recombinants expressing the Pr55gag protein precursor with or without Env protein produced abundant HIV virus-like
particles (VLPs) in addition to bullet-shaped VSV particles. HIV Env protein expressed from a VSV recombinant also
expressing Gag was specifically incorporated into the HIV VLPs but not into the VSV particles. In contrast, VSV G protein was
found in both VSV particles and in HIV VLPs. Such VSV/HIV recombinants producing HIV VLPs with Env protein could be an
effective source of HIV-like particles inducing both cellular and antibody-mediated immunity to HIV-1. © 2000 Academic Press
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(INTRODUCTION
Vesicular stomatitis virus (VSV) is an enveloped, non-
segmented, negative-stranded RNA virus and the proto-
type member of the family Rhabdoviridae (reviewed by
Wagner and Rose, 1996). The 11-kb wild-type viral ge-
nome codes for five structural proteins (Fig. 1): the nu-
cleocapsid (N) protein; the matrix (M) protein; the viral
glycoprotein (G), which mediates viral binding and host
cell fusion; and the phosphoprotein (P) and large protein
(L), which are subunits of the viral RNA-dependent RNA
polymerase. Each viral protein is translated from its own
subgenomic mRNA. The coding regions for each of the
viral mRNAs are separated by conserved sequences: an
11-nucleotide transcription stop sequence, including a
poly-A addition signal, an intergenic dinucleotide, and a
10-nucleotide transcription start signal. The viral poly-
merase attenuates transcription by approximately 30% at
each gene junction, such that upstream mRNAs (i.e., N)
are the most abundant and downstream mRNAs (i.e., L)
are the least abundant in infected cells (Iverson and
Rose, 1981).
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112The ability to recover fully infectious virus from plas-
mid DNAs encoding the VSV antigenome has allowed
the manipulation of the viral genome (Lawson et al.,
1995; Whelan et al., 1995). By duplicating the conserved
transcription start-stop signals, it has been possible to
express foreign genes from within the VSV genome
(Schnell et al., 1996b). High levels of both cellular and
viral membrane proteins have been expressed efficiently
from VSV recombinants (Schnell et al., 1996b; Johnson et
al., 1997; Kretzschmar et al., 1997; Schnell et al., 1997;
oberts et al., 1998; Schnell et al., 1998). Most foreign
iral glycoproteins are incorporated readily into VSV viri-
ns without any modifications to their sequences
Schnell et al., 1996a; Kretzschmar et al., 1997; Kahn et
l., 1999). However, the HIV-1 envelope protein is incor-
orated into VSV virions only if its cytoplasmic tail is
eplaced with the VSV G cytoplasmic tail (Johnson et al.,
997) or deleted to only three amino acids (Johnson et al.,
998).
The gag gene of HIV-1 encodes the internal viral struc-
ural proteins. In HIV-1 infected cells, the gag gene prod-
ct is translated from the full-length viral RNA into a
5-kDa precursor Pr55gag. This precursor is targeted to
he inner leaflet of the plasma membrane by virtue of the
otranslational myristoylation of an N-terminal glycine
Gottlinger et al., 1989). Once at the membrane, Pr55gag
molecules begin assembling into retroviral particles (re-
viewed by Gelderblom, 1991). A second precursor
Pr160gag-pol generated by ribosomal frameshifting at the 39
w
b
c
a
t
w
b
m
c
b
b
t
h
o
a
S
e
t
V
V
a ion to t
c
113CONSTRUCTION OF VSV RECOMBINANTSend of the gag region encompasses both the Gag and
Pol proteins (Jacks et al., 1988). The viral protease (PR)
ithin this precursor is activated near the time of particle
udding, allowing cleavage of the Gag precursor to its
onstituent matrix (MA), capsid (CA), nucleocapsid (NC),
nd p6 proteins (Vogt, 1996). This proteolytic processing
ransforms the immature HIV virions into the mature form
ith pyramid-shape cores.
Expression of the Pr55gag protein alone in cells has
een shown to result in the release into extracellular
edium of enveloped particles, termed virus-like parti-
les (VLPs). These VLPs contain Gag protein and resem-
le immature HIV particles (before proteolysis occurs) in
oth their size and shape (Gheysen et al., 1989; Karacos-
as et al., 1989; Mergener et al., 1992). Previous studies
ave shown that VLP production requires myristoylation
f Pr55gag, such that it is targeted to the plasma mem-
brane for assembly. Furthermore, like HIV-1 virions, VLPs
will incorporate the larger precursor Pr160gag-pol as well
s the HIV-1 envelope protein (Krausslich et al., 1993;
mith et al., 1993). Incorporation of the complete HIV
envelope protein requires the presence of the MA pro-
tein (Freed and Martin, 1996), whereas VLP production
itself occurs with a deletion of a substantial part of the
MA portion of Gag (Wang et al., 1998).
We report here the generation of recombinant VSVs
expressing the HIV-1 Gag precursor protein or both Gag
precursor and Env proteins. The HIV-1 Gag precursor is
FIG. 1. Diagram of VSV and recombinants expressing HIV proteins.
expressing HIV-1 Gag precursor or Gag precursor and Env are shown
ndonuclease sites used for constructing VSV recombinants in the pla
he cloning vector pVSV-MXA2 and the XhoI and NheI sites are in the p
SVgag5 expressed the gag gene as the fourth or fifth genes within t
SVgag4 construct are the unique sites employed to subclone the gag
l., 1997). These constructs expressed Gag precursor protein in addit
ytoplasmic domain of the VSV glycoprotein (VSVgagEnvG).produced in large quantities like the VSV proteins, and
generates abundant HIV VLPs containing Gag and VSV Gprotein. Infection with VSV recombinants expressing
both Gag and Env proteins resulted in the incorporation
of Env into VLPs but not into VSV virions.
RESULTS
Construction of VSV recombinants expressing HIV-1
Gag, Env, and Env-G hybrid proteins. To obtain expres-
sion of the HIV Gag precursor protein in a VSV recom-
binant, the Gag protein coding region was cloned into
expression sites between the M and G or between the G
and L genes in plasmid DNAs encoding the VSV anti-
genome. The gag gene employed here contains the
entire open reading frame of HIV-1 Gag protein and the
partially overlapping protease region of the pol gene.
Because previous experiments have shown that high-
level expression of active HIV-1 PR can interfere with VLP
formation, we used a construct containing a point muta-
tion (D25A) in the PR active site, thereby inactivating the
enzyme (Mergener et al., 1992). Figure 1 shows the
diagrams of the gene order for the gag recombinants
with numbers indicating the position of the gag gene
within the VSV genome. Because VSV transcription oc-
curs sequentially and is attenuated, we anticipated
higher Gag expression from VSVgag4 compared to VSV-
gag5. We were able to recover fully infectious viruses
from these plasmid constructs using methods described
previously (Lawson et al., 1995; Schnell et al., 1996b).
ne order in the vector based on wild-type VSV and VSV recombinants
9 to 59 orientation on the negative-stranded viral RNA. The restriction
NA representation of VSV are shown: The MluI and XmaI sites are in
2 vector (see under Materials and Methods). Constructs VSVgag4 and
ombinant VSV genome. The XbaI and SwaI sites indicated above the
nto the Env- or EnvG-containing VSV described previously (Johnson et
he HIV-1 Env protein (VSVgagEnv) or a chimeric Env protein with theThe ge
in a 3
smid D
VSV-XN
he rec
gene iBecause the HIV Env protein is not incorporated into
VSV particles (Johnson, Rodgers, and Rose, 1998), we
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114 HAGLUND ET AL.also sought to determine whether the HIV envelope gly-
coprotein would be incorporated into VLPs when coex-
pressed with the Gag precursor. To determine this, we
generated a recombinant VSV expressing both Gag and
Env proteins simultaneously (Fig. 1) as well as another
recombinant expressing Gag and an EnvG hybrid, in
which the VSV G cytoplasmic domain replaces the HIV
gp160 cytoplasmic domain allowing incorporation of Env
into VSV particles (Johnson et al., 1997, 1998). The plas-
mid constructs encoding both Env or EnvG with Gag
were generated by replacing the XbaI to SwaI fragments
in pVSV-Env and pVSV-EnvG (Johnson et al., 1997) with
the XbaI to SwaI fragment from pVSVgag4. These plas-
mids were used to recover VSV recombinants with gag
between M and G and the env or envG gene between G
and L. Each of these viruses encodes two additional
mRNAs and proteins from their genomes.
Expression of VSV and HIV proteins in infected cells.
To determine whether the recombinant VSVs correctly
expressed the appropriate HIV proteins in infected cells,
we analyzed proteins in extracts from [35S]methionine-
abeled infected cells. VSV causes shutoff of host cell
rotein synthesis during infection; thus, the major pro-
eins labeled in infected cell lysates are those expressed
y VSV. Figure 2 shows an SDS–polyacrylamide gel of
he labeled proteins present in cells infected with VSV or
he indicated recombinants (lanes 2–5). Cells infected
ith VSV (lane 1) expressed the expected VSV N, P, M, G,
nd L proteins. VSV recombinants expressing HIV Gag
rotein (Fig. 2, lanes 2–5) expressed the VSV proteins as
ell as an additional band at 55 kDa, corresponding to
he Gag precursor protein Pr55gag. VSVgagEnv (lane 4)
also expressed a protein corresponding in size to HIV
Env protein precursor gp160, while VSVgagEnvG ex-
pressed the gp160-VSV G hybrid protein precursor (lane
5). This protein migrates faster than gp160 because the
29-amino-acid VSV G cytoplasmic domain is much
shorter than the 150-amino-acid gp160 cytoplasmic do-
main. The identities of the HIV proteins were also con-
firmed by Western blotting for HIV Gag or HIV Env (data
not shown).
To determine whether the site of Gag expression
within the VSV genome influenced its level of expression,
the relative molar expression levels were determined by
Phosphorimager analysis using a correction for methio-
nine content of each protein. In the gel shown in Fig. 2,
the molar levels of Pr55gag expressed from both VSVgag4
nd VSVgag5 were approximately 40% that of VSV N.
hus, the movement of the gene did not give the ex-
ected 20–30% increase in protein expression seen in
ther cases (Kretzschmar et al., 1997; Roberts and Rose,
998), suggesting that something other than mRNA level
s limiting for Gag protein synthesis. The levels of Pr55gag
in both VSVgagEnv and VSVgagEnvG were similar to
those for VSVgag4. These viruses expressed the Env or
EnvG glycoproteins at approximately 30% the level of G.
t
VWe also used indirect immunofluorescence to confirm
that each of the proteins was expressed at the appropri-
ate location within cells. As expected, Pr55gag was local-
zed primarily within the cytoplasm of infected cells, and
nv and EnvG were primarily localized to the endoplas-
ic reticulum and the cell surface at later times after
nfection (data not shown).
Analysis of purified particles released from infected
ells. Based on previous studies of HIV Gag expression
Delchambre et al., 1989; Gheysen et al., 1989; Karacos-
tas et al., 1989; Haffar et al., 1990; Mergener et al., 1992;
Royer et al., 1992; Krausslich et al., 1993; Porter et al.,
1996), we expected that cells infected with VSVgag re-
combinants might produce HIV VLPs as well as VSV
virions. If VLPs were produced from infected cells, both
VSV proteins and Pr55gag should be found in particle form
n the supernatants of infected cells. To determine
hether VLPs were present, BHK cells were infected for
8 h until complete c.p.e. was observed. The superna-
ants were then collected, centrifuged to remove cell
ebris, and then centrifuged twice at 110,000g for 1 h
FIG. 2. Analysis of proteins expressed in infected cells. BHK cells
were infected with wild-type VSV or with the indicated recombinant
viruses. Five hours postinfection, cells were metabolically labeled with
[35S]methionine for 1 h, lysed, and cell lysates analyzed by SDS–PAGE.
oads were normalized for N protein content. Each lane represents
pproximately 2% of the lysate from 1 3 106 BHK cells. VSV proteins (N,
P, M, G, and L) are synthesized by all viruses. Additionally, a 55-kDa
protein corresponding to the Gag precursor Pr55gag is present in all
ag-expressing recombinants (lanes 2–5). The 160-kDa Env protein
recursor (gp160) is present in VSVgagEnv-infected cells (lane 4), and
faster migrating EnvG chimeric protein (gp160G) is present in cells
nfected with VSVgagEnvG (lane 5).hrough a layer of 10% sucrose to separate virus and
LPs from soluble proteins. SDS–PAGE with Coomassie
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115CONSTRUCTION OF VSV RECOMBINANTSblue staining of the purified virus is shown in Fig. 3. VSV
(lane 1) showed the five VSV proteins. All recombinants
expressing Gag showed an additional band of Pr55gag
(lanes 2–5), suggesting that the Gag protein was being
released in VLPs. All proteins were readily visualized by
Coomassie staining consistent with the high-level pro-
tein expression by VSV. VSV infection of 107 BHK cells
results in release of approximately 200 mg total VSV
protein in virions. Using [35S]methionine-labeling and
quantitation on the Phosphorimager, we determined that
HIV Gag represented approximately 15% of the total
protein in VSV and VLPs. Thus we estimate that approx-
imately 30 mg of HIV Gag protein precursor are released
rom 107 cells infected with VSVgag recombinants in 12
o 16 h.
Gag protein particles and VSV have different densities.
o distinguish between incorporation of Pr55gag into VLPs
or VSV particles, we initially tried separation based on
rate of sedimentation through sucrose gradients. Be-
cause this was not successful, we next determined
whether Gag and VSV proteins banded with different
densities on an equilibrium density gradient of 35–55%
sucrose. Plates of BHK cells were infected with VSV and
recombinants, labeled with [35S]methionine, and incu-
bated for 18–24 h. Virus particles were first purified by
FIG. 3. SDS–PAGE analysis of purified virus particles. BHK cells (1 3
107) were infected with the indicated viruses until the completion of
infection (18–24 h). The supernatants were cleared of cellular debris
and virus particles were separated from soluble protein by centrifuga-
tion (2 times) at 110,000g through a solution of 10% sucrose. Samples
were fractionated by SDS–PAGE followed by staining with Coomassie
blue. VSV proteins are seen in all lanes and Pr55gag was present in
urified supernatants from all recombinants expressing Gag (lanes
–5), but not in wild-type VSV control (lane 1). Env or EnvG proteins are
ot detected by Coomassie staining.sedimentation through 10% sucrose and then resus-
pended in 0.5 ml TE, and layered over a continuous35–55% sucrose gradient. The narrow range of sucrose
concentrations was used because both VSV and VLPs
have a density near that of 45% sucrose (Mergener et al.,
1992). Ultracentrifugation to equilibrium was for 18 h at
110,000g. Ten 1-ml fractions were then collected and
equal volumes of each fraction analyzed by SDS–PAGE
and visualized on a Phosphorimager. The results for two
of the VSV–HIV recombinants are shown in Figs. 4A and
4B.
As can be seen for VSVgag5 (Fig. 4A), the peak of the
VSV proteins (N, G, and M) was in fractions 4 and 5. The
FIG. 4. Separation of Gag protein particles from VSV particles by
equilibrium density gradient centrifugation. BHK cells were infected for
5 h with the indicated viruses and then metabolically labeled with
[35S]methionine for an additional 18 h. Culture supernatants were col-
lected, cleared of cellular debris, and purified by centrifugation
(110,000g) through a 10% sucrose solution. Pellets were resuspended
in 0.5 ml TE, pH7.6, and layered onto continuous 35–55% sucrose
gradients. Particles were then centrifuged to equilibrium density for
18 h at 110,000g. Ten 1-ml fractions were collected, and equal volumes
of each fraction were analyzed by SDS–PAGE. The top (;35% sucrose)
and the bottom (;55% sucrose) are indicated above each gel. The
sedimentation profiles for radiolabeled proteins were similar for both
VSVgag5 (A) and the double recombinant VSVgagEnv (B).
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116 HAGLUND ET AL.Gag protein peaked in fractions 6 and 7 and thus was
reasonably well separated from VSV. A similar separa-
tion was seen for VSV and Gag proteins in the double
recombinant VSVgagEnv (Fig. 4B). These results sug-
gested that Pr55gag was present in the form of particles
(VLPs) with slightly higher density than VSV virions. The
presence of VLPs was also confirmed by electron mi-
croscopy (negative stain) of particles as described later.
Expression of Gag results in incorporation of HIV
gp120 into the VLPs. Previous reports from our laboratory
showed that the HIV EnvG hybrid protein is incorporated
into VSV virions, whereas the native HIV Env protein is
not, because it contains a cytoplasmic signal that pre-
vents localization at VSV budding sites (Johnson et al.,
1998). Thus, the Env protein is not detectably released
into culture supernatants infected with a VSV recombi-
nant expressing Env (VSV-Env). To determine whether
Gag expression might allow native Env protein release
into culture supernatants via incorporation into VLPs, we
examined supernatants for the presence of gp120 by
Western blotting (Fig. 5). As reported previously, particles
produced by VSV-Env did not incorporate gp120 (lane 4),
whereas VSV-EnvG particles did incorporate EnvG (lane
5). In contrast, expression of Gag with Env allowed sub-
stantial release of Env into supernatants, suggesting
FIG. 5. Identification of Env protein in purified particles. BHK cells
(1 3 107) were infected with wild-type VSV (lane 1), VSV recombinants
xpressing both Gag precursor and Env or EnvG chimeric proteins
lanes 2 and 3), or recombinants expressing Env or EnvG chimeric
roteins alone (lanes 4 and 5). After 18–24 h, cellular debris was
emoved by centrifugation and virus particles were purified by two
ounds of centrifugation at 110,000g through a 10% sucrose solution.
otal protein content was determined for each sample by Pierce BCA
rotein assay and equal amounts of protein were then fractionated by
DS–PAGE. Proteins were transferred to nitrocellulose and blotted with
heep polyclonal anti-gp120 followed by biotin-conjugated rabbit anti-
heep antibody and HRP-conjugated streptavidin. Regions of HRP
eactivity were detected by ECL and exposure to Hyperfilm.incorporation of Env protein directly into VLPs (lane 2).
We also noted substantial, but variable amounts of un-cleaved gp160 in particles (lanes 2, 3, and 5), perhaps
because of saturation of the cellular furin protease re-
sponsible for its cleavage. The amount of Env present in
VSVgagEnv supernatants was comparable to that re-
leased in VSVgagEnvG and VSV-EnvG supernatants. The
band migrating at approximately 65 kDa is the VSV G
protein and is also seen in the VSV control lane. The
reason for the apparent cross-reactivity is not known.
Immunoelectron microscopy detects VLPs containing
the Env protein. To determine whether VLPs of the ex-
pected morphology were present in our samples, we
initially examined purified virus by electron microscopy
after negative staining. All culture supernatants contain-
ing viruses expressing Gag showed the presence of both
bullet-shaped VSV virions (;80% of the particles) as well
as VLPs (;20% of the particles). VLPs showed the typical
doughnut morphology with a diameter of 120 nm. Exam-
ples of VLPs and VSV virions are shown in Fig. 6, panels
C and D.
To determine whether Env protein was released into
culture supernatants by incorporation into VLPs, we an-
alyzed purified virus and VLPs by immunoelectron mi-
croscopy. BHK cells were infected with VSV recombi-
nants and the infection was allowed to proceed to com-
pletion. Purified virus was then labeled either with anti-G
mouse monoclonal antibodies (I1/I14) or with a combi-
nation of anti-gp41 (D61)/anti-gp120 V3 loop (D47) mouse
monoclonal antibodies. Immunogold-conjugated sec-
ondary antibodies were then used to detect the primary
antibodies.
Antibody to HIV Env detected Env protein in VLPs
produced by VSVgagEnv, but not in bullet-shaped VSV
particles produced by the same virus (panel C) or in
wild-type VSV (panel A). In contrast, anti-G protein anti-
bodies detected G protein in wild-type VSV particles
(panel B) and in bullet-shaped particles produced by
VSVgagEnv and in VLPs produced by VSVgagEnv (panel
D). Thus G protein is freely incorporated into both VLPs
and VSV, while Env is restricted to VLPs. The lack of
incorporation of Env into VSV particles confirms previous
studies from our laboratory (Owens and Rose, 1993;
Johnson et al., 1997). We therefore conclude that Env is
released from VSVgagEnv infected cells by incorporation
into VLPs.
Growth of the VSV/HIV recombinants. To determine the
effect of the extra gene or genes on growth of the VSV
recombinants, we analyzed final virus titers in a one-step
growth experiment. From previous studies, we knew that
maximal titers were obtained between 8 and 16 h after a
high-multiplicity infection. Therefore, after a high-multi-
plicity infection with VSV recombinants, followed by re-
moval of the inoculum, samples of culture supernatant
were collected at 9, 12.5, and 16 h postinfection and
titered by standard plaque formation assay.Table 1 shows the titers obtained from each virus at
these time points. Both VSVgag4 and VSVgag5 parallel
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117CONSTRUCTION OF VSV RECOMBINANTSthe growth of VSV over time and reach peak titers similar
to wild-type VSV by 12.5 h postinfection. The growth of
VSVgagEnv and VSVgagEnvG appeared to be somewhat
slower than VSV or VSVgag recombinants. However, the
titers of these viruses were only three- to fourfold less
than wild-type at 16 h, demonstrating a relatively small
effect on virus growth by the addition of 40% more RNA
to the genome. Despite the fact that the gagEnv virus
grew to lower titers than wild-type VSV, we did not ob-
serve loss of Gag or Env expression even after ten
passages.
DISCUSSION
We describe here the characterization of VSV recom-
binants expressing the HIV-1 Gag protein alone or the
Gag protein with either HIV-1 Env or a chimeric Env
protein containing the cytoplasmic domain of VSV G.
FIG. 6. Incorporation of Env and VSV G into VSV and VLPs. Cells we
irus samples were adsorbed to carbon-coated EM grids and stained
), or with mouse monoclonal anti-VSV-G antibody (B and D). Primary
T
Viral Titers at Nine to
Hours post-
infection w.t VSV VSV gag5
9 4.2 3 107 3.2 3 107
12 2.9 3 108 1.7 3 10816 2.2 3 108 2.4 3 108These recombinants expressed high levels of the Env
and/or Gag proteins in infected cells within 5 h of infec-
tion (Fig. 2). Pr55gag was expressed at high levels like
VSV proteins and approximately 30 mg Pr55gag was re-
leased from 107 BHK cells infected with VSVgag after
2–16 h. Both recombinant VSV progeny and VLPs con-
aining Pr55gag were assembled and released from cells
nfected with all recombinant VSVs expressing HIV-1 Gag
Figs. 3, 4, 6). Furthermore, we found that during the
udding process, VLPs incorporated HIV-1 Env protein,
hile HIV-1 Env was not incorporated into bullet-shaped
SV particles (Figs. 5 and 6).
Thus, we describe a propagating virus producing sub-
tantial quantities of VLPs containing both Gag and Env
roteins. For comparison, under optimal conditions, T
ells cocultured with HIV-1 infected cells yield 40 to 160
mg of Gag protein per 107 cells after 36 h of acute
cted with the indicated viruses for 18 h and virus purified as in Fig. 3.
combination of mouse anti-gp120 (D60) plus mouse anti-gp41 (A and
y was detected with a 14-nm gold-conjugated antimouse Fc antibody.
Hours Postinfection
iral titers (pfu/ml)
VSV gag4 VSV gagEnv VSV gagEnvG
3.4 3 107 1.1 3 106 9.9 3 106
1.3 3 108 2.5 3 107 2.1 3 107re infeABLE 1
Sixteen
V1.1 3 108 7.3 3 107 6.0 3 107
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118 HAGLUND ET AL.infection (H.-G. Kra¨usslich, unpublished observations).
Thus, the VSV recombinant system is similar to an opti-
mized HIV system for HIV protein production.
The recombinant genome of VSVgagEnv contains
about 15.4 kb of RNA in comparison to the 11.1 kb of the
wild-type VSV genome. This represents a 40% increase
in genome size and raises the recombinant VSV genome
into the size range of the Paramyxoviridae, the next
argest family of Mononegavirales in terms of genome
ize. The VSVgagEnv recombinant is the largest recom-
inant rhabdovirus constructed so far and, given the only
hreefold effect on virus titer, it is likely that significantly
ore RNA could be added to the VSV genome without
reventing growth of the recombinant. The minimal effect
f the size increase on titer is likely due to the helical
ature of the VSV nucleocapsid which can grow in length
Schnell et al., 1996a). This contrasts with many other
NA viruses which must pack their RNAs within an
cosahedral shell of defined dimensions and thus are
uite limited in the amount of foreign genetic material
hat can be packaged.
VLP production has been documented in other sys-
ems expressing the Gag proteins of HIV-1 and other
etroviruses (Delchambre et al., 1989; Gheysen et al.,
989; Karacostas et al., 1989; Haffar et al., 1990; Merge-
ner et al., 1992; Royer et al., 1992; Krausslich et al., 1993;
Porter et al., 1996). A major advantage of the VSV system
is the accommodation of both HIV Gag and Env expres-
sion from a single replication competent virus and the
production of substantial quantities of HIV VLPs contain-
ing HIV envelope. Furthermore, VSV vectors can be
grown in a wide variety of mammalian cells, including
those already approved for vaccine production. It can
also be used to vaccinate animals at mucosal surfaces
(Roberts et al., 1998, 1999).
The gag gene construct that we employed in our
studies contains the entire Gag coding region with all of
the overlapping protease gene (Mergener et al., 1992).
Because VLP assembly does not occur efficiently in the
presence of an active protease gene, the protease gene
product was inactivated by a D25A mutation in the active
site (Mergener et al., 1992). We also recovered a VSV
recombinant with an analogous Gag construct lacking
the D25A mutation, but we were not able to detect gag
gene products produced by this virus on SDS–PAGE.
Also, it did not produce VLPs as expected.
We found that VLPs encoded by VSVgagEnv incorpo-
rated both VSV G and HIV-1 Env protein into their mem-
branes. The HIV-1 MA protein sequences within the
55-kDa Gag precursor play an important role in limiting
or mediating glycoprotein incorporation into nascent
HIV-1 virions or VLPs. Based on the results of mutagen-
esis studies and studies in vitro on Env-MA interactions,
it has been proposed that there exists a direct interaction
between N-terminal portions (leu 12) of MA and the
C-terminal 67 amino acids of Env (Freed et al., 1994;Freed and Martin, 1995; Cosson, 1996; Freed and Martin,
1996). The limitation that these interactions place on
glycoprotein incorporation seem to apply to HIV-1 Env
but not to retroviral glycoproteins with shorter cytoplas-
mic domains (Mammano et al., 1995). Similarly, the fact
that the VSV G cytoplasmic domain is only 29 amino
acids may account for our observation that G is incorpo-
rated into HIV VLPs.
Prior characterization in our laboratory of a VSV re-
combinant expressing HIV-1 Env protein revealed that
Env is largely excluded from VSV virions (Johnson et al.,
1997). The length alone of the Env cytoplasmic tail (150
amino acids) is not responsible for its exclusion, since
truncation of the tail to 10 amino acids still did not allow
Env incorporation into VSV particles. Rather, there is a
plasma membrane localization signal in the membrane
proximal 10 amino acids of Env that excludes it from sites
of VSV budding (Johnson et al., 1998). However, replace-
ment of the cytoplasmic tail with that of VSV G in the
EnvG chimeric protein allows incorporation of the chi-
meric protein into VSV (Johnson et al., 1997). We have
shown here that the coexpression of Gag protein from
VSV provides an additional means of export of Env into
particles released from cells without the need to alter the
native sequence of Env protein.
VSV is a highly effective vaccine vector in animals and
is known to elicit strong antibody and cell-mediated
immunity to expressed proteins (Zinkernagel et al., 1978;
Dietzschold et al., 1996; Roberts et al., 1998, 1999). Pre-
liminary studies in rhesus monkeys (J. Rose, D. Nixon,
and P. Marx, unpublished data) have shown that live
recombinant VSVs expressing HIV Env protein alone are
nonpathogenic and elicit potent cell-mediated and anti-
body responses to HIV Env. Viruses expressing both
HIV-1 Gag and Env proteins and releasing VLPs contain-
ing Env may prove especially useful as live vaccine
vectors for HIV. Although the correlates of HIV immunity
are as yet unclear, evidence points to the importance of
both neutralizing antibody against Env and cell-mediated
immunity against Gag, Pol, and Env epitopes (reviewed
by Haynes et al., 1996). It has already been demonstrated
that purified VLPs alone are capable of eliciting both
antibody and cytotoxic T-lymphocyte (CTL) responses
against Gag and Env proteins (Haffar et al., 1991; Wagner
et al., 1994, 1996a,b). Because the Env protein expressed
from VSV recombinants is functional (Johnson et al.,
1997; Boritz et al., 1999), it must be in a native conforma-
tion. This native conformation may be important for the
generation of neutralizing antibodies that often recognize
complex epitopes in oligomeric Env protein (Sattentau
and Moore, 1995).
With the emerging promise of VSV as a vaccine vector,
and the known immunogenicity and inherent stability of
VLPs, the VSV/VLP combination vector described here
may prove to be an effective strategy for HIV-1 vaccina-
tion. VSV has the advantage over other vectors, such as
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119CONSTRUCTION OF VSV RECOMBINANTSthose derived from poxviruses or alphaviruses, of incor-
porating HIV envelope into its own membrane. VSV is
also a small virus expressing only five proteins to com-
pete for immune responses (compared to hundreds ex-
pressed by poxviruses) and does not generate any
known immunosuppressive proteins.
MATERIALS AND METHODS
Plasmids and DNA constructs. The source of the gag
ene used in these studies was pBluescript-gpIIa (Mer-
ener et al., 1992), which contains the entire sequence
ncoding the HIV-1 Gag and the 59 portion of pol includ-
ing the protease region. PR activity was eliminated by a
substitution mutation (D25A) in the PR active site.
Figure 1 shows the locations of restriction sites used
for cloning into the full-length antigenomic VSV vectors
pVSV-XN2 (Schnell et al., 1996b) and pVSV-MXA2
(Kretzschmar et al., 1997). pVSVgag5 contains the gag
gene between the VSV G and L genes in the pVSV-XN2
vector. It was constructed by ligating the 1.98-kb product
of pBSgpIIa digestion with XhoI (upstream) and XbaI
(downstream) into the XhoI- and XbaI-compatible NheI
sites in pVSV-XN2. To construct pVSVgag4 containing the
gag gene between the VSV M and G genes, gag was
amplified by PCR from pBSgpIIa using the forward primer
59-GC GGC CGC CTC GAG ACG CGT AAG ATG GGT
GCG AGA GCG TCA-39, introducing a unique MluI site
(underlined) and overlapping the Gag start codon (itali-
cized) at the 59 end; and the reverse primer 59-GA TCG
TC CCC GGG TTA TTG TGA CGA GGG GTC GT-39,
introducing a unique XmaI site (underlined). The PCR
fragment was digested with MluI and XmaI and ligated
into the MluI and XmaI sites of the pVSV-MXA2 vector.
To construct the plasmids pVSVgagEnv and pVSVgag-
EnvG, pVSVgag4 was digested at a unique XbaI site in P
and a unique SwaI site in G (Fig. 1). The resulting 2.73-kb
fragment containing gag was subcloned into the unique
XbaI and SwaI sites of either pVSV-gp160 or pVSV-89.6G,
yielding pVSVgagEnv and pVSVgagEnvG, respectively.
As described (Johnson et al., 1997), pVSV-gp160 contains
the env gene of the laboratory-adapted IIIb strain of
HIV-1 between the G and L genes, and pVSV-89.6G
contains the env gene of the dual-tropic, 89.6 strain of
HIV-1 with its cytoplasmic domain replaced with that of
VSV G.
Virus recoveries. Infectious recombinant VSVs were
recovered from the cDNA constructs as previously de-
scribed (Lawson et al., 1995; Schnell et al., 1996b). Briefly,
10-cm plates of BHK cells were infected for 30 min at a
multiplicity of infection (m.o.i.) of 10 with vTF7–3, a re-
combinant vaccinia virus expressing the T7 RNA poly-
merase (Fuerst et al., 1986). The vTF7–3 inoculum was
removed and cells were transfected simultaneously with
four plasmids: 10 mg of one of the VSV antigenomic
constructs (pVSVgag4, pVSVgag5, pVSVgagEnv, or pVS-VgagEnvG), 3 mg pBS-N expressing VSV N, 5 mg pBS-P,
and 2 mg pBS-L coding for the P and L subunits of the
VSV polymerase. After 3 h, the transfection medium was
changed to Dulbecco’s modified Eagle medium supple-
mented with 5% fetal bovine serum (DMEM-5). After 2
days, residual vaccinia was removed from culture super-
natants by filtration through a 0.2-mm filter onto fresh
BHK cells. Plates positive for recombinant VSV were
identified by the presence of VSV cytopathic effect (c.p.e.)
and by indirect immunofluorescence against VSV pro-
teins.
Metabolic labeling of cells. BHK cells (;1.5 3 105)
ere infected with each recombinant VSV at a m.o.i. of
0–20 for 30 min in serum-free DMEM (SF-DMEM). In-
ections were then incubated for an additional 4.5 h in
MEM-5. Media was then replaced with methionine-free
MEM plus 100 mCi [35S]methionine (Easy tag EXPRESS
protein labeling mix; NEN Life Sciences) and cells were
then incubated at 37oC for 1 h. Cells were lysed on ice for
15 min in 500 ml lysis buffer (1% Nonidet-P40; 0.4%
eoxycholate; 66 mM EDTA; and 10 mM Tris–Cl, pH 7.4).
uclei were removed by centrifugation for 2 min at room
emperature in an Eppendorf centrifuge and superna-
ants were transferred to a new tube. Protein extracts (10
ml of each sample) were fractionated by SDS–polyacryl-
amide gel electrophoresis (SDS–PAGE, 10% acrylamide)
and proteins visualized on a Phosphorimager (Molecular
Dynamics). The N protein content in each sample was
quantitated (ImageQuant software), and sample volumes
normalized for N content. Samples were then refraction-
ated by SDS–PAGE.
One-step growth analysis. BHK cells (1 3 106) on 6-cm
ishes were infected with VSV recombinants at a m.o.i. of
0–50 for 30 min in SF-DMEM. The cells were washed
our times with SF-DMEM to remove the virus inoculum.
he media was replaced with DMEM-5 and cells incu-
ated at 37°C. Samples (100 ml) of infectious superna-
ant were drawn from plates at 9, 12.5, and 16 h postin-
ection and diluted in a 10-fold series for titering on BHK
ells by plaque assay. After each sample was taken, the
ell culture volume was replenished with 100 ml fresh
MEM-5.
Analysis of purified VSV virions and VLPs. BHK cells
;1 3 106) in 10-cm dishes were infected with wild-type
VSV or recombinant VSVs at a m.o.i. of 0.01 for 30 min in
SF-DMEM. The inoculum was then aspirated and re-
placed with DMEM-5. Infections were allowed to pro-
ceed for 18 to 24 h until there was a complete cytopathic
effect. Virus supernatants were collected and clarified of
cellular debris by centrifugation at 1250g for 10 min at
room temperature. Clarified supernatants were then cen-
trifuged through a 10% sucrose solution (all sucrose
solutions are given as w/v) in TE (10 mM Tris–Cl, pH 7.6;
1 mM EDTA) in a Beckman SW41Ti rotor for 1 h at
110,000g at 4°C. The viral pellets were resuspended in
500 ml TE, and recentrifuged through a 10% sucrose
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120 HAGLUND ET AL.solution as above. Viral pellets were resuspended in 200
ml TE, and 10 ml analyzed by SDS–PAGE followed by
staining with 0.05% Coomassie brilliant blue (Bio-Rad).
Western blotting for gp120. Virus was grown and pu-
rified as described above. Each sample was normalized
for protein content using the Pierce BCA protein assay.
Equal amounts of protein (10 mg) for each sample were
fractionated by SDS–PAGE and transferred to nitrocellu-
lose at 40 mA for 16 h at 4°C. Nitrocellulose was blocked
in 5% milk in TTBS (0.02% Tween 20; 0.9% NaCl; 100 mM
Tris–HCl, pH 7.5) overnight, followed by three 5-min
washes in TTBS. The primary antibody was sheep anti-
gp120 (NIH AIDS Research and Reference Reagent Pro-
gram) and was diluted 1:2000 for use in 5% milk–TTBS.
The nitrocellulose was incubated with the primary anti-
body for 1 h at room temperature. The nitrocellulose was
then washed three times for 5 min in TTBS and incubated
with the secondary antibody Biotin-conjugated rabbit an-
tisheep (Vector Laboratories) at 1:10,000 dilution for 1 h,
followed by washing. Blots were then incubated for 1 h
with HRP-conjugated streptavidin (Vector Laboratories)
at 1:10,000 in 5% milk-TTBS followed by washing. Anti-
gp120 reactive bands were visualized by chemilumines-
cence (ECL reagents, Amersham).
Separation of VSV from VLPs by equilibrium sedimen-
tation. BHK cells (1 3 106) were infected at 0.01 m.o.i. in
F-DMEM for 30 min. Infections were then allowed to
roceed an additional 3.5 h in DMEM-5. To radiolabel
irions and VLPs, the infection medium was replaced
ith methionine-free DMEM supplemented with 10%
MEM (containing methionine) and 5% FBS as well as
00 mCi [35S]methionine Trans label (NEN). Infections
were then allowed to proceed for 18 h, at which time
$80% of cells exhibited VSV c.p.e. Culture supernatants
were collected and cleared of debris by centrifuging for
10 min at 1250g at room temperature. Clarified superna-
tants were purified by centrifugation through 10% su-
crose once, as described above. The resulting viral pel-
lets were then resuspended in 500 ml TE and layered
nto continuous 35–55% sucrose gradients in TE. The
radients were then centrifuged at 110,000g for 18 h at
°C. Twelve 1-ml fractions were collected from each
radient from the top down. Each fraction was then
iluted in the appropriate volume of TE so that the final
ucrose concentration was less than 10%. VSV and VLPs
ere pelleted from diluted fractions by centrifugation at
5,000 rpm at 4°C for 1 h in a Tomy MTX-150 refrigerated
abletop centrifuge. The viral pellets were suspended in
0 ml sample buffer and analyzed by SDS–PAGE followed
by visualization with a Phosphorimager.
Electron microscopy. Virus for electron microscopy
(EM) was grown on BHK cells (1 3 106) on 10-cm dishes
nfected at a 0.01 m.o.i. Supernatants were precleared by
entrifugation for 10 min and purified twice by sedimen-ation through 10% sucrose as described above. The final
ellet was resuspended in 500 ml TE. Virus was ad-
Gsorbed to carbon-coated EM grids by floating the grid on
a 50-ml droplet of virus for 10 min. The grids were
locked for 45 min in 1% bovine serum albumin (BSA) in
BS. The primary antibodies were mouse monoclonal
nti-gp120 (Ab D47) and mouse monoclonal anti-gp41
Ab D61) (both courtesy of Dr. Robert Doms, U. Pennsyl-
ania), and each was used at a dilution of 1:100 in 1%
SA–PBS. Grids were incubated with primary antibodies
or 1 h and washed four times in 1% BSA–PBS. The
econdary antibody was 14-nm gold-conjugated anti-
ouse Fc (Auroprobe, Amersham) incubated with grids
ndiluted for 1 h followed again by four washes. Grids
ere negative stained for 5 min with 2% phosphotungstic
cid, pH 7.5, and air-dried. Images were obtained with a
eiss EM910 electron microscope.
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